Scholarlink

<p>The close connection between heart and kidney diseases was described as early as the nineteenth&#xa0;century. Today it is evident that both organ systems are closely linked by hemodynamic, hormonal and inflammatory mechanisms. The cardiorenal syndrome describes acute or chronic dysfunction in one organ that adversely affects the other. Due to the close association to metabolic diseases, the concept of cardiorenal metabolic syndrome is becoming increasingly more established. In addition to children and adolescents with primary cardiac or nephrological diseases, numerous chronic conditions are associated with an elevated risk of premature cardiovascular and renal damage. Early identification of risk groups, structured screening and interdisciplinary care along with the establishment of new biomarkers and imaging techniques, are essential in order to reduce long-term cardiorenal morbidity and mortality. In this context, the establishment of specialized cardiorenal units and the rapid development and approval of new medications, such as sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists, play a&#xa0;pivotal role.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Kardiorenale Medizin in der Pädiatrie – neuer Fokus in Prävention und Therapie

  • 期刊论文

  • 发表日期：

    2025年7月31日

查看全文
  • Johannes Holle,
  • Lutz T. Weber,
  • Hannes Sallmon,
  • Johannes Nordmeyer,
  • Dominik Müller

摘要

The close connection between heart and kidney diseases was described as early as the nineteenth century. Today it is evident that both organ systems are closely linked by hemodynamic, hormonal and inflammatory mechanisms. The cardiorenal syndrome describes acute or chronic dysfunction in one organ that adversely affects the other. Due to the close association to metabolic diseases, the concept of cardiorenal metabolic syndrome is becoming increasingly more established. In addition to children and adolescents with primary cardiac or nephrological diseases, numerous chronic conditions are associated with an elevated risk of premature cardiovascular and renal damage. Early identification of risk groups, structured screening and interdisciplinary care along with the establishment of new biomarkers and imaging techniques, are essential in order to reduce long-term cardiorenal morbidity and mortality. In this context, the establishment of specialized cardiorenal units and the rapid development and approval of new medications, such as sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists, play a pivotal role.